| # | Title | Journal | Year | Citations |
|---|
| 1 | A systematic review of the associations between dose regimens and medication compliance | Clinical Therapeutics | 2001 | 2,040 |
| 2 | Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice | Clinical Therapeutics | 1999 | 710 |
| 3 | Capecitabine: A review | Clinical Therapeutics | 2005 | 584 |
| 4 | Recognition and treatment of hyponatremia in acutely ill hospitalized patients | Clinical Therapeutics | 2007 | 570 |
| 5 | Current Challenges in Cancer Treatment | Clinical Therapeutics | 2016 | 549 |
| 6 | Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity | Clinical Therapeutics | 2000 | 545 |
| 7 | Immunogenicity of therapeutic proteins: Clinical implications and future prospects | Clinical Therapeutics | 2002 | 508 |
| 8 | The cost of treating community-acquired pneumonia | Clinical Therapeutics | 1998 | 488 |
| 9 | Evaluating quality-of-life and health status instruments: development of scientific review criteria | Clinical Therapeutics | 1996 | 482 |
| 10 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study | Clinical Therapeutics | 2006 | 475 |
| 11 | Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies | Clinical Therapeutics | 2006 | 473 |
| 12 | The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma | Clinical Therapeutics | 2015 | 469 |
| 13 | Childhood Obesity: A Review of Increased Risk for Physical and Psychological Comorbidities | Clinical Therapeutics | 2013 | 464 |
| 14 | Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation | Clinical Therapeutics | 2015 | 437 |
| 15 | Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir | Clinical Therapeutics | 2001 | 413 |
| 16 | Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer | Clinical Therapeutics | 1999 | 406 |
| 17 | Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials | Clinical Therapeutics | 2003 | 388 |
| 18 | Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study | Clinical Therapeutics | 2007 | 387 |
| 19 | Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study | Clinical Therapeutics | 2007 | 371 |
| 20 | Overview of Classical Test Theory and Item Response Theory for the Quantitative Assessment of Items in Developing Patient-Reported Outcomes Measures | Clinical Therapeutics | 2014 | 367 |
| 21 | A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids | Clinical Therapeutics | 2001 | 365 |
| 22 | Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations | Clinical Therapeutics | 2005 | 363 |
| 23 | Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study | Clinical Therapeutics | 2000 | 353 |
| 24 | A Review of Diabetes Treatment Adherence and the Association with Clinical and Economic Outcomes | Clinical Therapeutics | 2011 | 342 |
| 25 | Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability | Clinical Therapeutics | 2004 | 332 |
| 26 | Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases | Clinical Therapeutics | 2008 | 330 |
| 27 | IBM Watson: How Cognitive Computing Can Be Applied to Big Data Challenges in Life Sciences Research | Clinical Therapeutics | 2016 | 328 |
| 28 | Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study | Clinical Therapeutics | 2008 | 323 |
| 29 | Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update | Clinical Therapeutics | 2008 | 312 |
| 30 | Predictors of medication adherence in the elderly | Clinical Therapeutics | 1998 | 308 |
| 31 | A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia | Clinical Therapeutics | 2007 | 303 |
| 32 | Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort study | Clinical Therapeutics | 2003 | 294 |
| 33 | Herb and supplement use in the US adult population | Clinical Therapeutics | 2005 | 293 |
| 34 | Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review | Clinical Therapeutics | 2017 | 292 |
| 35 | Safety of doxycycline and minocycline: A systematic review | Clinical Therapeutics | 2005 | 291 |
| 36 | Continuation of initial antihypertensive medication after 1 year of therapy | Clinical Therapeutics | 1998 | 288 |
| 37 | The bone quality framework: Determinants of bone strength and their interrelationships, and implications for osteoporosis management | Clinical Therapeutics | 2005 | 288 |
| 38 | Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies | Clinical Therapeutics | 2001 | 287 |
| 39 | Diabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy | Clinical Therapeutics | 2018 | 286 |
| 40 | Mechanism of Action of Colchicine in the Treatment of Gout | Clinical Therapeutics | 2014 | 285 |
| 41 | Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of alzheimer's disease | Clinical Therapeutics | 1998 | 281 |
| 42 | Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study | Clinical Therapeutics | 2003 | 279 |
| 43 | Overview of patient compliance with medication dosing: a literature review | Clinical Therapeutics | 1984 | 277 |
| 44 | Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials | Clinical Therapeutics | 2007 | 272 |
| 45 | A review of the receptor-binding and pharmacokinetic properties of dopamine agonists | Clinical Therapeutics | 2006 | 267 |
| 46 | Therapeutic drug monitoring of immunosuppressant drugs in clinical practice | Clinical Therapeutics | 2002 | 264 |
| 47 | Evaluating the quality of life of patients with restless legs syndrome | Clinical Therapeutics | 2004 | 263 |
| 48 | Viscosupplementation with Hylan G-F 20: A 26-week controlled trial of efficacy and safety in the osteoarthritic knee | Clinical Therapeutics | 1998 | 262 |
| 49 | Pregabalin: A novel γ-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders | Clinical Therapeutics | 2007 | 259 |
| 50 | Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 Diabetes | Clinical Therapeutics | 2006 | 258 |
